Form 4: TransMedics Director Thomas Gunderson Receives RSU Grant

Director Thomas J. Gunderson acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of an equity grant.

Summary

• Director Thomas J. Gunderson was granted 2,922 restricted stock units (RSUs) on May 20, 2026.
• Each RSU represents a contingent right to receive one share of TransMedics Group, Inc. common stock.
• Following this transaction, the director's total beneficial ownership of common stock increased to 6,981 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• The grant of equity aligns the director's interests with those of shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices intended to incentivize long-term oversight and alignment with shareholder value.

Comparison to Industry Standards

• The issuance of RSUs to directors is a standard practice among mid-cap medical technology companies to ensure board retention and alignment.
• The transaction size is consistent with typical annual equity compensation packages for non-employee directors in the healthcare sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• The RSUs will vest according to the company's standard equity incentive plan terms.

Key Dates

Keywords

TransMedics, TMDX, Form 4, Insider Trading, Director Compensation, Equity Grant